Receptor for advanced glycation end products involved in lung ischemia reperfusion injury in cardiopulmonary bypass attenuated by controlled oxygen reperfusion in a canine model

ASAIO J. 2013 May-Jun;59(3):302-8. doi: 10.1097/MAT.0b013e318290504e.

Abstract

Controlled oxygen reperfusion could protect the lung against ischemia-reperfusion injury in cardiopulmonary bypass (CPB) by downregulating high mobility group box 1 (HMGB1), a high affinity receptor of HMGB1. This study investigated the effect of controlled oxygen reperfusion on receptor for advanced glycation end products (RAGE) expression and its downstream effects on lung ischemia-reperfusion injury. Fourteen canines received CPB with 60 minutes of aortic clamping and cardioplegic arrest followed by 90 minutes of reperfusion. Animals were randomized to receive 80% FiO2 during the entire procedure (control group) or to a test group receiving a controlled oxygen reperfusion protocol. Pathologic changes in lung tissues, RAGE expression, serum interleukin-6 (IL-6), and tumor necrosis factor-α (TNF-α) were evaluated. The lung pathologic scores after 25 and 90 minutes of reperfusion were significantly lower in the test group compared with the control group (p < 0.001). RAGE expression, TNF-α, and IL-6 were downregulated by controlled oxygen treatment (p < 0.001). RAGE might be involved in the lung ischemia-reperfusion injury in canine model of CPB, which was downregulated by controlled oxygen reperfusion.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Blotting, Western
  • Cardiopulmonary Bypass / adverse effects*
  • Disease Models, Animal
  • Dogs
  • Female
  • Glycation End Products, Advanced / metabolism*
  • Interleukin-6 / blood*
  • Lung / metabolism
  • Lung / pathology*
  • Lung / physiopathology
  • Male
  • Oxygen / pharmacology*
  • Receptor for Advanced Glycation End Products
  • Receptors, Immunologic / metabolism*
  • Reperfusion Injury / drug therapy*
  • Reperfusion Injury / metabolism*
  • Reperfusion Injury / pathology
  • Reverse Transcriptase Polymerase Chain Reaction
  • Tumor Necrosis Factor-alpha / blood*

Substances

  • Glycation End Products, Advanced
  • Interleukin-6
  • Receptor for Advanced Glycation End Products
  • Receptors, Immunologic
  • Tumor Necrosis Factor-alpha
  • Oxygen